BillionToOne Responds to Inaccurate and Misleading Short Seller Report
Key Highlights
- ➤BillionToOne rejects Fuzzy Panda Research’s report as inaccurate, distorted, and misleading
- ➤BillionToOne says its compliance, billing, assistance, and commercial practices follow applicable laws
- ➤BillionToOne says SEC filings are accurate and complete in all material respects
- ➤BillionToOne is reviewing legal options related to the short seller report
Expert Statements
Oguzhan Atay, Co-Founder and CEO of BillionToOne
“Every day, clinicians and families rely on BillionToOne’s tests at some of the most consequential moments of their care, and we take that responsibility seriously.”
Oguzhan Atay, Co-Founder and CEO of BillionToOne
“We built this company on rigorous science, transparency, and doing right by patients. I am proud of our team, and we remain focused on delivering for the patients, providers and shareholders who count on us.”
MENLO PARK, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company today responded to a report published on November 18, 2026 by Fuzzy Panda Research, a short seller that, by its own disclosure, holds a short position in BillionToOne securities and stands to profit from driving down the company’s stock price.
BillionToOne believes the report contains numerous inaccurate, distorted, unsupported, and highly misleading claims. The report relies heavily on anonymous sources, selectively presented data, and speculative extrapolation to reach conclusions that BillionToOne categorically rejects.
Get started
Create a free account to read the full story.
